Relmada Therapeutics, Inc.Company Review & Valuation

OTC Markets

About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases, primarily depression and chronic pain in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for Show morethe treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab ER, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is based in New York, New York.Show less

Drug Manufacturers - Specialty & Generic
HQ Location
New York, New York

Stock Price

Price data not available for Relmada Therapeutics, Inc..


Please login or create a free account to view the contents of this section.

Similar Companies

Momenta Pharmaceuticals
Merck (India)

back to top